SYDNEY, AUSTRALIA - Immutep Limited (ASX:IMM;NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$872,351 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2018 fiscal year, mainly related to the Company’s TACTI-mel trial, a Phase I clinical study in melanoma using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.
Immutep will apply the funding towards furthering its current active clinical trial programs for its lead product, IMP321.
For further information please download PDF attached:
Download this document